Publications by authors named "Sharon E Crugnale"
Article Synopsis
- Lp-PLA2 is linked to inflammation in heart disease, and darapladib is an oral inhibitor aimed at reducing this risk after acute coronary syndrome (ACS).
- The SOLID-TIMI 52 trial enrolled 13,026 participants globally to compare the effects of darapladib versus placebo over a median follow-up of 2.5 years.
- Results indicated no significant differences in major coronary events or overall mortality between the darapladib and placebo groups, suggesting darapladib may not effectively improve outcomes post-ACS.
Background: Vitamin K antagonists have been the standard oral antithrombotic used for more than a half century for prevention and treatment of thromboembolism. Their limitations include multiple food and drug interactions and need for frequent monitoring and dose adjustments. Edoxaban is a selective and direct factor Xa inhibitor that may provide effective, safe, and more convenient anticoagulation.
View Article and Find Full Text PDF